

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/LCFF5814D97AEN.html>

Date: December 2019

Pages: 156

Price: US\$ 3,500.00 (Single User License)

ID: LCFF5814D97AEN

Abstracts

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019'; Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 53 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.

The report 'Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019' outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are

being developed by Companies / Universities.

It also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 1, 28 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Glioblastoma Multiforme (GBM), Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Marginal Zone B-cell Lymphoma, Melanoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Cerebral (Fatal) Malaria, Chronic Lymphocytic Leukemia (CLL), Colon Carcinoma, Diabetic Retinopathy, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Myeloproliferative Disorders, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Peripheral T-Cell Lymphomas (PTCL), Sezary Syndrome, Thymic Carcinoma and Transitional Cell Cancer (Urothelial Cell Cancer).

SCOPE

The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects

The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in

Therapeutics Development

Abpro Corp

ALX Oncology Inc

Arch Oncology Inc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biocad

Bristol-Myers Squibb Co

EpicentRx Inc

Forty Seven Inc

GeneScience Pharmaceuticals Co Ltd

GigaGen Inc

Hummingbird Bioscience Pte Ltd

I-Mab Biopharma Co Ltd

ImmuneOncia Therapeutics LLC

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

KAHR medical Ltd

LynkCell Inc
MesaGen LLC
NovImmune SA
Opsyon
Paradigm Shift Therapeutics LLC
Phanes Therapeutics Inc
PharmAbcine Inc
Shanghai Henlius Biotech Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
TOT Biopharm Co Ltd
Trillium Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or
Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ABP-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abpro Corp, H2 2019
Pipeline by ALX Oncology Inc, H2 2019
Pipeline by Arch Oncology Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Biocad, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by EpicentRx Inc, H2 2019
Pipeline by Forty Seven Inc, H2 2019
Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019

Pipeline by ImmuneOncia Therapeutics LLC, H2 2019
Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by KAHR medical Ltd, H2 2019
Pipeline by LynkCell Inc, H2 2019
Pipeline by MesaGen LLC, H2 2019
Pipeline by NovImmune SA, H2 2019
Pipeline by Opsyon, H2 2019
Pipeline by Paradigm Shift Therapeutics LLC, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Sorrento Therapeutics Inc, H2 2019
Pipeline by Surface Oncology Inc, H2 2019
Pipeline by Synthon Holdings BV, H2 2019
Pipeline by TOT Biopharm Co Ltd, H2 2019
Pipeline by Trillium Therapeutics Inc, H2 2019
Pipeline by Waterstone Hanxbio Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Abpro Corp

ALX Oncology Inc

Arch Oncology Inc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biocad

Bristol-Myers Squibb Co

EpicentRx Inc

Forty Seven Inc

GeneScience Pharmaceuticals Co Ltd

GigaGen Inc

Hummingbird Bioscience Pte Ltd

I-Mab Biopharma Co Ltd

ImmuneOncia Therapeutics LLC

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

KAHR medical Ltd

LynkCell Inc

MesaGen LLC

NovImmune SA

Opsyon

Paradigm Shift Therapeutics LLC

Phanes Therapeutics Inc

PharmAbcine Inc
Shanghai Henlius Biotech Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
TOT Biopharm Co Ltd
Trillium Therapeutics Inc
Waterstone Hanxbio Pty Ltd

I would like to order

Product name: Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/LCFF5814D97AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LCFF5814D97AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970